|
Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas. |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Celularity; Chimerix; Day One Biopharmaceuticals; Genenta Science; GlaxoSmithKline; Insightec; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novartis; Novocure; Novocure; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals; VBI Vaccines |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Chimerix (Inst); Erasca, Inc (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst) |
| |
|
Stock and Other Ownership Interests - Lilly |
| |
|
Consulting or Advisory Role - Alexion (Astra Zeneca); SpringWorks Therapeutics |
Research Funding - Chimerix; VBI Vaccines |
| |
|
Consulting or Advisory Role - GammaTile; Istari; PharPoint Research |
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst) |
(OPTIONAL) Uncompensated Relationships - Actuate Therapeutics; Chimerix |
| |
|
Honoraria - Epitopoietic Research Corporation |
| |
|
No Relationships to Disclose |
| |
|
Employment - VBI Vaccines |
Leadership - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Patents, Royalties, Other Intellectual Property - As Chief Scientific Officer at VBI Vaccines, I am an inventor on much of the company's patent, including that of VBI-1901 (the subject of submitted abstract). |
Travel, Accommodations, Expenses - VBI Vaccines |
| |
|
Honoraria - Clinical Education Alliance |
Consulting or Advisory Role - Affinia Therapeutics; BioClinica; Global Coalition for Adaptive Research; Leal Therapeutics; Orbus Therapeutics; RadMD as an expert blinded independent reviewer of clinical and imaging data for a Roche-sponsored trial; Sapience Therapeutics; Servier |
Research Funding - Abbott Laboratories (Inst); Abbvie (Inst); Aeterna Zentaris (Inst); Bayer (Inst); Biohaven Pharmaceuticals (Inst); BMS (Inst); Chimerix (Inst); Corden (Inst); DelMar Pharmaceuticals (Inst); Genentech/Roche (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Kintara Therapeutics (Inst); NextSource (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Polaris (Inst); QED Therapeutics (Inst); Servier (Inst); VBI Vaccines (Inst); Vigeo Therapeutics (Inst) |
Travel, Accommodations, Expenses - Abbvie; Anheart Therapeutics; Bridgebio; Chimerix; Foundation Medicine; Gilead Sciences; Global Coalition for Adaptive Research; Helsinn Healthcare; Servier; VBI Vaccines |
| |
|
Stock and Other Ownership Interests - Praesidia Biotherapeutics |
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Anheart Therapeutics; ClearView Healthcare Partners; Gennao Bio; Guidepoint Global; Kiyatec; Massive Bio; Medtronic; Merck; MimiVax; Novocure; Ono Pharmaceutical; PPD; Praesidia Biotherapeutics; Regeneron; tocagen; Xcures |
Speakers' Bureau - Prime Oncology |
Research Funding - ABM (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); FORMA Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Pfizer (Inst); Sapience Therapeutics (Inst); tocagen (Inst) |
Travel, Accommodations, Expenses - Oncoceutics |
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics |